RecruitingNCT06401889

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

Sponsor

Mayo Clinic

Enrollment

25 participants

Start Date

Jul 19, 2024

Study Type

OBSERVATIONAL

Conditions

This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.

Sex: FEMALEMin Age: 18 Years

\* Female ≥ 18 years
Postmenopausal women suitable to receive aromatase inhibitor as per physician's discretion
Histologically confirmed adenocarcinoma of the breast stage 0-III with estrogen receptor (ER) and/or progesterone receptor (PR) positive per American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guideline and any human epidermal growth factor receptor 2 (HER2)
Patients must not have received any prior chemotherapy or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included
Patients willing to avoid any facial procedures including facials, neurotoxin injections, fillers, or lasers during study period
Willing and able to provide consent

\* Patients who have previously taken AIs
Patients using prescription tretinoin, neurotoxin injections, fillers, facial lasers, microneedling, or facials within 6 months of study consent

OTHERNon-Interventional Study

Non-interventional study

Mayo Clinic in Florida

Jacksonville, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT06401889